MARKET

ADXS

ADXS

Advaxis
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.3701
+0.0100
+2.78%
Pre Market: 0.3651 -0.005 -1.35% 08:16 10/30 EDT
OPEN
0.3602
PREV CLOSE
0.3601
HIGH
0.3801
LOW
0.3601
VOLUME
1.29M
TURNOVER
--
52 WEEK HIGH
1.480
52 WEEK LOW
0.2625
MARKET CAP
24.51M
P/E (TTM)
-0.6138
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Advaxis down 12% despite ADXS-503 shows sustained tumor control in mid-stage lung cancer trial
Advaxis (ADXS) announces updated clinical results from the combination arm of its Phase 1/2 study evaluating ADXS-503 in combination with Merck's (MRK) KEYTRUDA (pembrolizumab), an anti-PD-1 therapy in non-small cell lung
Seekingalpha · 3d ago
Advaxis' ADXS-503 Demonstrates Pronounced, Sustained Tumor Control In Ongoing Phase 1/2 Lung Cancer Trial
Advaxis' ADXS-503 (HOT Lung) Demonstrates Pronounced and Sustained Tumor Control in Ongoing Phase 1/2 Lung Cancer Trial Disease control rate of 67% in first six evaluable patients who had progressed
Benzinga · 4d ago
Advaxis To Present Data From Ongoing ADXS-503 Phase 1/2 Clinical Trial At SITC 2020
Advaxis to Present Data from Ongoing ADXS-503 Phase 1/2 Clinical Trial at SITC 2020 PRINCETON, N.J., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company focused on
Benzinga · 10/15 12:18
Advaxis to Present Data from Ongoing ADXS-503 Phase 1/2 Clinical Trial at SITC 2020
PRINCETON, N.J., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced it will present an ePoster at the 35th Annual Meeting of the Society for Immunology of Cancer (SITC 2020) to be held virtually November 9-14, 2020. Title: “Phase 1/2 Study of an Off-the-Shelf, Multi-Neoantigen Vector (ADXS-503) Alone and in Combination with Pembrolizumab in Subjects with Metastatic Non-Small Cell Lung Cancer (NSCLC)” Presenter: Dr. Jonathan W. Goldman. University of California Los Angeles, Santa Monica, CA Abstract ID: 360 Date and Time: Thursday, November 12th from 4:50 pm until 5:20 pm ET and Saturday, November 14th from 1:00 pm until 1:30 pm ET.The poster will be available on Advaxis’ website at https://www.advaxis.com/events-and-presentationsAbout Advaxis, Inc. Advaxis, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Lm-based antigen delivery products. These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-based strains are believed to be a significant advancement in immunotherapy as they integrate multiple functions into a single immunotherapy and are designed to access and direct antigen presenting cells to stimulate anti-tumor T cell immunity, activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable T cells to eliminate tumors.To learn more about Advaxis, visit www.advaxis.com and connect on Twitter, LinkedIn, Facebook and YouTube.Investor Contact Tim McCarthy LifeSci Advisors, LLC Tim@lifesciadvisors.com (212) 915-2564
GlobeNewswire · 10/15 12:00
Advaxis, Inc. Adopts Limited Duration Stockholder Rights Plan
PRINCETON, N.J., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that its Board of Directors has approved the adoption of a limited duration stockholder
GlobeNewswire · 09/29 13:30
Advaxis on go with early-stage study with ADXS-504 in prostate cancer
The FDA has signed off investigator sponsored Phase 1 trial for Advaxis' (ADXS) ADXS-504, off-the-shelf neoantigen ADXS-HOT program candidate for prostate cancer.The company plans to launch the study with ADXS-504 monotherapy for prostate cancer before
Seekingalpha · 09/24 12:34
Advaxis Announces FDA Clearance of New IND for ADXS-504 for Treatment of Prostate Cancer
Strategic transition to Investigator sponsored IND from previously announced Advaxis sponsored INDInitiation of investigator sponsored Phase 1 study of ADXS-504 in prostate cancer on-track for Q4 2020PRINCETON, N.J., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology
GlobeNewswire · 09/24 12:00
Advaxis Q3 EPS $(0.09) Up From $(1.00) YoY
Advaxis (NASDAQ:ADXS) reported quarterly losses of $(0.09) per share. This is a 91 percent increase over losses of $(1.00) per share from the same period last year.
Benzinga · 09/10 12:13
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ADXS. Analyze the recent business situations of Advaxis through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ADXS stock price target is 5.00 with a high estimate of 5.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 58
Institutional Holdings: 7.54M
% Owned: 11.39%
Shares Outstanding: 66.23M
TypeInstitutionsShares
Increased
8
163.44K
New
13
533.26K
Decreased
8
468.14K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.04%
Pharmaceuticals & Medical Research
+0.17%
Key Executives
Chairman/Independent Director
David Sidransky
President/Chief Executive Officer/Chief Financial Officer/Director
Kenneth Berlin
Non-Executive Vice Chairman/Independent Director
James Patton
Executive Vice President
Andres Gutierrez
Independent Director
Roni Appel
Independent Director
Richard Berman
Independent Director
Samir Khleif
Independent Director
Richard Schwalm
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ADXS
Advaxis, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-LLO strains integrate multiple functions into a single immunotherapy as they access and direct antigen presenting cells to stimulate anti-tumor T-cell immunity, stimulate and activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable the T-cells to eliminate tumors. Axalimogene filolisbac is its lead Lm-LLO immunotherapy product candidate for the treatment of Human Papilloma Virus-associated cancers. ADXS-PSA is its Lm-LLO immunotherapy product candidate that targets the Prostate Specific Antigen (PSA) associated with prostate cancer.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Advaxis, Inc. stock information, including NASDAQ:ADXS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADXS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ADXS stock methods without spending real money on the virtual paper trading platform.